Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 8, 2007

View Archived Issues

Sunitinib safe and active in phase II hepatocellular carcinoma study

Phase I trial compares daily, twice daily ARRY-543 in patients with solid tumors

Safety demonstrated by RTS,S/AS02D malaria vaccine encourages phase III study

FDA grants a second orphan drug designation to Thrombotargets for TT-103MH

Human Genome Sciences completes enrollment in ACHIEVE 2/3 phase III trial of Albuferon

The National Institutes of Health awards Progenics with grants totaling USD 1.9 million

Phase III mifamurtide data confirms superior overall survival in osteosarcoma

huC242-DM4: preclinical studies and a phase I trial

MEDI-528 well tolerated to date in phase II asthma trial

Analyses highlight efficacy of ambrisentan in pulmonary arterial hypertension

Dynavax and Merck & Co. enter global license agreement to jointly develop Heplisav

CV Therapeutics reports positive data from phase I study of CVT-6883

European AIDS Conference: Studies of atazanavir/ritonavir

Agents for arthritis and other inflammatory disorders disclosed in recent patents

Recent patents cover new therapeutic agents for cancer

FDA approves Epeius's phase II registration protocol of Rexin-G for osteosarcoma

Immtech completes trial of pafuramidine for prevention of malaria

FDA extends action date for priority review of Regeneron's BLA for rilonacept

Takeda's TAK-442 enters into phase II clinical stage for venous/arterial thromboembolism

Insmed initiates phase II clinical trial of Iplex for myotonic muscular dystrophy

Gentium seeks amendment to phase III trial of defibrotide for hepatic veno-occlusive disease

Generex administers first dose in phase I clinical trial of AE-37 vaccine peptide

Vectura reports positive data from second phase II clinical study of VR-040

GeoVax reports positive data from full-dose phase I HIV/AIDS vaccine human trial

Recent Allergan patent describes novel antiglaucoma agents

Gilead and LG Life Sciences enter license agreement to develop caspase inhibitors

Merck Serono submits MAA for sapropterin in the treatment of HPA

Preclinical profile of a novel triple reuptake inhibitor from Roche

V1b receptor antagonist Org-52186 reduces stress-induced HPA axis hyperactivity

nAChR alpha7 full agonist with procognitive and neuroprotective properties